Latest Breaking News On - Hematologic malignancies leukemia - Page 1 : comparemela.com

Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress

Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesSteven steinEuropean hematology associationEuropean medicines agencyMyeloproliferative neoplasms biology translational researchDrug administrationExchange commissionIncyte corporationAmerican society of clinical oncologyMyeloproliferative neoplasms biology transitional researchXencor incLymphoma biology translational researchClinical oncologyAnnual meetingChief medical officerSelect advanced solid tumors

ASCO 2024 | Ascentage Pharma To Present Four Studies, Including An Oral Report Featuring The Latest Data Of Olverembatinib In SDH-Deficient GIST

ASCO 2024 | Ascentage Pharma To Present Four Studies, Including An Oral Report Featuring The Latest Data Of Olverembatinib In SDH-Deficient GIST
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesMccormick placeHong kongHaibo qiuMasa lasicaHuafeng wangYifan zhaiAscentage pharmaYuxiang maPrnewswire ascentage pharmaNational reimbursement drug listZhejiang university school of medicineMajor nationalAmerican society of clinical oncologySun yat sen university cancer centerMd anderson cancer center

Data from Across Incyte s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress

Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from across its oncology portfolio will be presented at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual

United kingdomUnited statesTafasitamab monjuviGewinn nurCatalina lovemanPonatinib iclusigSteven steinGreg shertzerEuropean hematology associationLymphoma biology translational researchXencor incMacrogenics incMarrow transplant researchEuropean unionMillennium pharmaceuticals incIncyte corporation

Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Showcase Rapidly Expanding Oncology Pipeline and Advances in Current Product Portfolio at ASCO 2023

Data from multiple studies of investigational bispecific drug zanidatamab, including pivotal Phase 2 biliary tract cancers (BTC) trial results, demonstrate breakthrough HER2-targeted pan-tumor

Palo altoUnited statesKristin bhavnaniPharma marZymework azymetricRob iannoneAndrean flynnJazz pharmaceuticalsFrench early access programDrug administrationAmerican society of clinical oncologyJazz pharmaceuticals incExchange commissionUniversity of texas md anderson cancer centerDepartment of gastrointestinal medical oncologyPrnewswire jazz pharmaceuticals

Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Present Data Showcasing Clinical Advancements Across Oncology Portfolio at 2022 ASCO and EHA Meetings

Key data includes ASCO oral presentation of data from the Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) Phase 2/3 trial in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma DUBLIN

United statesVyxeos liposomalKristin bhavnaniAndrean flynnRob iannoneCalles blancoJazz pharmaceuticals incCommission file noOncology centerAmerican society of clinical oncologyChildren oncology groupEuropean commissionJazz pharmaceuticalsEuropean hematology associationDrug administrationHead of global corporate communications